Expert Interview
Discussing the potential of Vaxcyte's VAX-31 and VAX-24, pneumococcal conjugate vaccine (PCV) candidates designed to prevent invasive pneumococcal disease (IPD)
Ticker(s): PCVX, MRK, PFEInstitution: Montgomery Infectious Disease Associates
- Infectious Disease Physician at Montgomery Infectious Disease Associates
- Board Certified in Internal Medicine and Infectious Diseases; inducted as a Fellow of the American College Of Physicians in 2003.
- Manages patients with a wide variety of infectious diseases; extensive experience with the treatment and management of HIV/AIDS.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
